GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Caliway Biopharmaceuticals Co Ltd (TPE:6919) » Definitions » Beneish M-Score

Caliway Biopharmaceuticals Co (TPE:6919) Beneish M-Score : -2.98 (As of Mar. 30, 2025)


View and export this data going back to 2022. Start your Free Trial

What is Caliway Biopharmaceuticals Co Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.98 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Caliway Biopharmaceuticals Co's Beneish M-Score or its related term are showing as below:

TPE:6919' s Beneish M-Score Range Over the Past 10 Years
Min: -2.98   Med: -2.15   Max: -1.31
Current: -2.98

During the past 6 years, the highest Beneish M-Score of Caliway Biopharmaceuticals Co was -1.31. The lowest was -2.98. And the median was -2.15.


Caliway Biopharmaceuticals Co Beneish M-Score Historical Data

The historical data trend for Caliway Biopharmaceuticals Co's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Caliway Biopharmaceuticals Co Beneish M-Score Chart

Caliway Biopharmaceuticals Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Beneish M-Score
Get a 7-Day Free Trial - - - -1.31 -2.98

Caliway Biopharmaceuticals Co Quarterly Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.31 - -2.66 - -2.98

Competitive Comparison of Caliway Biopharmaceuticals Co's Beneish M-Score

For the Biotechnology subindustry, Caliway Biopharmaceuticals Co's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Caliway Biopharmaceuticals Co's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Caliway Biopharmaceuticals Co's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Caliway Biopharmaceuticals Co's Beneish M-Score falls into.


;
;

Caliway Biopharmaceuticals Co Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Caliway Biopharmaceuticals Co for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.5755+0.528 * 1.0192+0.404 * 0.4984+0.892 * 1.1413+0.115 * 0.7922
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 2.319+4.679 * -0.006808-0.327 * 0.2552
=-2.98

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec24) TTM:Last Year (Dec23) TTM:
Total Receivables was NT$5.18 Mil.
Revenue was 9.363 + 23.257 + 7.848 + 3.966 = NT$44.43 Mil.
Gross Profit was 6.847 + 16.008 + 5.254 + 2.652 = NT$30.76 Mil.
Total Current Assets was NT$9,706.05 Mil.
Total Assets was NT$9,770.51 Mil.
Property, Plant and Equipment(Net PPE) was NT$61.32 Mil.
Depreciation, Depletion and Amortization(DDA) was NT$29.51 Mil.
Selling, General, & Admin. Expense(SGA) was NT$97.79 Mil.
Total Current Liabilities was NT$52.74 Mil.
Long-Term Debt & Capital Lease Obligation was NT$3.00 Mil.
Net Income was -56.138 + -137.57 + -176.65 + -218.472 = NT$-588.83 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = NT$0.00 Mil.
Cash Flow from Operations was -42.005 + -119.474 + -200.605 + -160.225 = NT$-522.31 Mil.
Total Receivables was NT$7.89 Mil.
Revenue was 14.906 + 8.795 + 11.528 + 3.703 = NT$38.93 Mil.
Gross Profit was 10.754 + 6.501 + 7.74 + 2.474 = NT$27.47 Mil.
Total Current Assets was NT$3,743.63 Mil.
Total Assets was NT$3,826.50 Mil.
Property, Plant and Equipment(Net PPE) was NT$80.41 Mil.
Depreciation, Depletion and Amortization(DDA) was NT$27.87 Mil.
Selling, General, & Admin. Expense(SGA) was NT$36.95 Mil.
Total Current Liabilities was NT$73.68 Mil.
Long-Term Debt & Capital Lease Obligation was NT$11.87 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(5.184 / 44.434) / (7.892 / 38.932)
=0.116667 / 0.202712
=0.5755

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(27.469 / 38.932) / (30.761 / 44.434)
=0.705564 / 0.692285
=1.0192

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (9706.053 + 61.316) / 9770.507) / (1 - (3743.631 + 80.409) / 3826.503)
=0.000321 / 0.000644
=0.4984

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=44.434 / 38.932
=1.1413

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(27.867 / (27.867 + 80.409)) / (29.505 / (29.505 + 61.316))
=0.25737 / 0.32487
=0.7922

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(97.788 / 44.434) / (36.946 / 38.932)
=2.200747 / 0.948988
=2.319

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((2.998 + 52.744) / 9770.507) / ((11.874 + 73.679) / 3826.503)
=0.005705 / 0.022358
=0.2552

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-588.83 - 0 - -522.309) / 9770.507
=-0.006808

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Caliway Biopharmaceuticals Co has a M-score of -2.98 suggests that the company is unlikely to be a manipulator.


Caliway Biopharmaceuticals Co Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Caliway Biopharmaceuticals Co's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Caliway Biopharmaceuticals Co Business Description

Traded in Other Exchanges
N/A
Address
No.99, Sec. 1, Xintai 5th Road, 32rd Floor-9, Xizhi District, New Taipei City, TWN, 221
Caliway Biopharmaceuticals Co Ltd is specialized in the development of new drugs for medical aesthetic and inflammatory diseases. Its pipeline candidate is, CBL-514, CBA-539, and CBO-012.

Caliway Biopharmaceuticals Co Headlines

No Headlines